<DOC>
	<DOCNO>NCT00871494</DOCNO>
	<brief_summary>Azithromycin potent vitro activity broad spectrum typical atypical bacteria anaerobe . Azithromycin intravenous formulation demonstrate high efficacy eradication rate western clinical trial . Development azithromycin intravenous formulation would bring clinical benefit patient pelvic inflammatory disease ( PID ) Japan .</brief_summary>
	<brief_title>Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease ( PID ) In Japan</brief_title>
	<detailed_description />
	<mesh_term>Pelvic Inflammatory Disease</mesh_term>
	<mesh_term>Pelvic Infection</mesh_term>
	<criteria>Both follow symptom observe . Lower abdominal pain and/or low abdominal tenderness . Hypochondrial pain and/or hypochondrial tenderness ( tenderness uterus adnexa uterus ) . Known suspected hypersensitivity intolerance azithromycin , macrolides , ketolides . Hepatic dysfunction ( AST , ALT , total bilirubin &gt; 3 time institutional normal ) .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>